about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Au­toim­mune biotech Kiniksa prices up­sized $152M IPO as Schol­ar Rock bags $75M for pre­clin­i­cal SMA drug

7 years ago
Financing

Astel­las shed­ding 600-plus jobs as CEO shakes up R&D and sales ops in re­struc­tur­ing

7 years ago
R&D
Pharma

FDA chief Got­tlieb is build­ing a reg­u­la­to­ry speed­way to ac­cel­er­ate gene ther­a­py de­vel­op­ment

7 years ago
Pharma
Cell/Gene Tx

Fight­ing for a place in the ul­cer­a­tive col­i­tis mar­ket, Sub­lim­i­ty rais­es $64M for an al­ter­na­tive drug to an­ti-TNF

7 years ago
Financing

Grail hauls in mon­ster $300M round from Chi­nese in­vestors amid ru­mors about Hong Kong IPO

7 years ago
Financing
China

Bay Area start­up Rain Ther­a­peu­tics nabs $18M Se­ries A to tar­get lung can­cer niche

7 years ago
Financing
Startups

GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

7 years ago
News Briefing

Roche adds a stel­lar round of piv­otal da­ta on Hem­li­bra, look­ing to ex­pand its mar­ket for a po­ten­tial mega-block­buster

7 years ago
R&D

Roivant brings Pfiz­er vets Azoulay, Gul­fo in­to its C-suite; Aileron CEO Joseph Yanchik is out

7 years ago
Peer Review

Al­ler­gan faces fresh woes with Resta­sis patents as Wal­green, re­tail­ers file law­suit over 'an­ti­com­pet­i­tive con­duc­t'

7 years ago
Pharma

Who’s de­lay­ing gener­ic com­pe­ti­tion? FDA pub­lish­es a long list of drug­mak­ers they say gamed the sys­tem

8 years ago
Pharma

FDA faults IQVIA for er­rors in opi­oid sales da­ta, calls for qual­i­ty re­view

8 years ago
Pharma

As­traZeneca steps up its use of Em­u­late's 'or­gan chip' tech; An­sun Bio­phar­ma's parain­fluen­za ther­a­py at­tracts $85M ...

8 years ago
News Briefing

EIP Phar­ma flies in­to a high-risk PhI­Ib Alzheimer’s study fu­eled with $20.5M from bil­lion­aire Len Blavat­nik’s ...

8 years ago
Financing

Medicxi, RA Cap­i­tal join $30M round for Dutch biotech's late-stage trans­plan­ta­tion med

8 years ago
Financing

Cam­bridge spin­out Cell­Cen­tric gets $26M for sin­gle-as­set epi­ge­net­ics ap­proach to prostate can­cer

8 years ago
Financing

Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

8 years ago
R&D
Pharma

Jose Car­los 'JC' Gutiér­rez-Ramos hits the ex­it at Syn­log­ic; Rich Hey­man pass­es Oric reins to ex-Igny­ta CFO

8 years ago
Peer Review

Whisky, se­crets, and code names: be­hind-the-scenes of Takeda's $62B Shire bid - Bloomberg

8 years ago
Deals

As­traZeneca's star res­pi­ra­to­ry drug runs in­to an­oth­er wall with COPD, but it's not giv­ing up — yet

8 years ago
R&D

Chi­na's CStone bags $260M Se­ries B for am­bi­tious I/O work, ex­pand­ing its list of mar­quee in­vestors

8 years ago
Financing
China

Temasek, cor­po­rate VCs buy in­to pre­scrip­tion dig­i­tal med hopes in Ak­il­i's $55M Se­ries C

8 years ago
Financing

List­ing in Shang­hai, WuXi AppTec rais­es a $354M IPO for Chi­na R&D fa­cil­i­ties

8 years ago
Financing
Outsourcing

Set to be the first pre-rev­enue biotech to list in Hong Kong, As­cle­tis lays out pri­or­i­ties in IPO ap­pli­ca­tion

8 years ago
Financing
China
First page Previous page 116117118119120121122 Next page Last page
A service from the Financial Times